2024
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
Thomas S, Pico B, Henick B, Leidner R, Samhouri Y, Isaacs J, Weiss J, Hurwitz M, Grewal J, Luke J, Chattopadhyay S, Wang Y, Motta M, Murray J, Barton D, Pinchasik D, MacBeath G, Moser J. Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors. Journal Of Clinical Oncology 2024, 42: 2542-2542. DOI: 10.1200/jco.2024.42.16_suppl.2542.Peer-Reviewed Original ResearchT-cell receptor-engineered T-cell therapyLoss of heterozygositySolid tumorsHLA-A*02:01HLA matchingHLA allelesPatients evaluated to dateFirst-in-human clinical trialDose level 1Dose level 3Pre-identify patientsTarget HLA alleleAntitumor T cellsT-cell therapyLoss of heterozygosity testingT-cell attackMaster protocolProportion of patientsScreening protocolCombination of HLAHLA LOHHLA lossImmunosuppressive microenvironmentMAGE-A1HLA typing
2022
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19
Sacco K, Castagnoli R, Vakkilainen S, Liu C, Delmonte OM, Oguz C, Kaplan IM, Alehashemi S, Burbelo PD, Bhuyan F, de Jesus AA, Dobbs K, Rosen LB, Cheng A, Shaw E, Vakkilainen MS, Pala F, Lack J, Zhang Y, Fink DL, Oikonomou V, Snow AL, Dalgard CL, Chen J, Sellers BA, Montealegre Sanchez GA, Barron K, Rey-Jurado E, Vial C, Poli MC, Licari A, Montagna D, Marseglia GL, Licciardi F, Ramenghi U, Discepolo V, Lo Vecchio A, Guarino A, Eisenstein EM, Imberti L, Sottini A, Biondi A, Mató S, Gerstbacher D, Truong M, Stack MA, Magliocco M, Bosticardo M, Kawai T, Danielson JJ, Hulett T, Askenazi M, Hu S, Cohen J, Su H, Kuhns D, Lionakis M, Snyder T, Holland S, Goldbach-Mansky R, Tsang J, Notarangelo L. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nature Medicine 2022, 28: 1050-1062. PMID: 35177862, PMCID: PMC9119950, DOI: 10.1038/s41591-022-01724-3.Peer-Reviewed Original ResearchConceptsInflammatory syndromeSevere acute respiratory syndrome coronavirus 2Pediatric coronavirus disease 2019Acute respiratory syndrome coronavirus 2Robust type I interferon (IFN) responseRespiratory syndrome coronavirus 2Pediatric COVID-19Pediatric healthy controlsSignatures of inflammationMultisystem inflammatory syndromeTime of admissionSyndrome coronavirus 2Combination of HLAT cell clonotypesType I interferon responseCoronavirus disease 2019Multi-institutional studyCOVID-19Minority of childrenT cell activationI interferon responseType II IFNSubstantial morbidityCoronavirus 2PCR status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply